Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;17(2):108-123.
doi: 10.1038/s41571-019-0281-6. Epub 2019 Nov 8.

From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer

Christopher Nevala-Plagemann  1 , Manuel Hidalgo  2 , Ignacio Garrido-Laguna  3   4
Affiliations
Review

From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer

Christopher Nevala-Plagemann et al. Nat Rev Clin Oncol. 2020 Feb.

Abstract

Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have lagged behind advances made in the treatment of many other malignancies over the past few decades. For most patients with PDAC, cytotoxic chemotherapy remains the mainstay of treatment. For patients with resectable disease, modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) is the standard-of-care adjuvant therapy, although data from several randomized trials have shown improved outcomes with neoadjuvant treatment strategies. For patients with advanced-stage or metastatic disease, comprehensive genomic profiling has revealed several potentially actionable alterations in small subsets of patients and the feasibility of implementing such strategies is beginning to be confirmed. Novel therapies targeting certain aberrations, most notably BRCA1/2 mutations, mismatch repair (MMR) deficiencies or NTRK1-3 fusions, have shown considerable activity in clinical trials, and larotrectinib, entrectinib and pembrolizumab have received FDA approval for the treatment of patients with tumours harbouring NTRK fusions and MMR deficiencies, respectively, regardless of primary tumour histology. In this Review, we describe the available data on the activity of these and other agents in patients with PDAC. Our discussion is structured according to the acronym 'PRIME' to organize the various treatment strategies currently undergoing evaluation in clinical trials: Pathway inhibition, alteration of DNA Repair pathways, Immunotherapy, cancer Metabolism and targeting the Extracellular tumour microenvironment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Roser, M. & Ritchie, H. Cancer. Our World in Data https://ourworldindata.org/cancer (2018).
    1. Kalager, M., Zelen, M., Langmark, F. & Adami, H. O. Effect of screening mammography on breast-cancer mortality in Norway. N. Engl. J. Med. 363, 1203–1210 (2010). - PubMed - DOI
    1. Lauby-Secretan, B. et al. The IARC perspective on colorectal cancer screening. N. Engl. J. Med. 378, 1734–1740 (2018). - PubMed - PMC - DOI
    1. Vasen, H. et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J. Clin. Oncol. 34, 2010–2019 (2016). - PubMed - DOI
    1. Canto, M. I. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 155, 740–751.e742 (2018). - PubMed - DOI

MeSH terms

LinkOut - more resources